Brain Scientific’s partner, LOK Corporation, will illustrate the benefits of expanding access to EEG with Brain Scientific’s neurology products
LAKEWOOD RANCH, Fla., May 04, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Brain Scientific (OTCQB: BRSF) today announces that its new neurological products will be showcased at the NATO Center of Excellence for Military Medicine as an innovative and potentially life-saving tool for armed forces personnel.
“Improving the accessibility and proximity of care is a constant challenge for the military. LOK is thrilled to introduce NeuroCap™ to the COE of NATO and help them achieve this goal,” said Daniel Cloutier, Founder and CEO of LOK Corporation.
Currently, patients must await transport to a hospital or clinic to undergo EEG testing to determine brain injury or neurological conditions. Once there, they can wait for hours or even overnight to see a neurology technician. With Brain Scientific’s NeuroCap™ device, any field physician can record EEG data in remote locations, greatly expanding accessibility to EEG. The disposable, lightweight and easy-to-use NeuroCap can be a vital tool for field physicians and other medical personnel wherever EEG testing is needed most.
“While the NeuroCap has proven itself in research and in clinical settings,” said Hassan Kotob, CEO of Brain Scientific. “We believe our NeuroCap and NeuroEEG can save lives in the field, especially for military personnel and populations in conflict zones. We look forward to the NATO Center of Excellence for Military Medicine embracing the strength and benefits of our technology.
About Brain Scientific
Scientific Brain (brainscientific.com) is a medical technology company with multiple patents and FDA-approved products. Brain Scientific is committed to developing next-generation solutions that advance the future of neurodiagnostic and OEM medical devices. Brain Scientific offers two product lines covering neurology and precision movement. The NeuroCap and NeuroEEG are intelligent neurodiagnostic devices that simplify administration, shorten analysis time and reduce costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of medical devices. To learn more about Brain Scientific’s corporate strategy, products, or investor relations, please visit brainscientific.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, but are not limited to, statements regarding (i) management’s plans and objectives for future operations, including plans or objectives relating to the design, development and commercialization of products and EEG services and piezo motor technology; (ii) a projection of revenue (including income/loss), earnings (including earnings/loss) per share, capital expenditure, dividends, capital structure or other financial items; (iii) the company’s future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in (i), (ii), (iii) or (iv) above. These forward-looking statements are not intended to predict or guarantee actual results, performance, events or circumstances and may not be realized as they are based on current projections, plans, objectives, beliefs, expectations, estimates and assumptions. of the company and are subject to a number of risks and uncertainties and other influences, over which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described in the forward-looking statements due to these risks and uncertainties. Factors that could influence or contribute to the inaccuracy of forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company’s inability to obtain additional financing; the considerable time and resources associated with product development and the associated insufficient cash flow and resulting illiquidity; the company’s inability to expand its business; significant government regulation of the medical devices and healthcare industry; lack of product diversification; volatility in the price of the Company’s raw materials; and failure to implement business plans or corporate strategies. Some of these and other factors are identified and described in greater detail in the company’s filings with the SEC. The company does not undertake to update these forward-looking statements.
Los Angeles, California